Reply:

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/86969/1/24520_ftp.pd

Progress in hepatitis B: A 30‐year journey through three continents

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107540/1/hep27120.pd

Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/147072/1/hep41281.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/147072/2/hep41281_am.pd

Endpoints of hepatitis B treatment

The goal of hepatitis B treatment is to prevent the development of cirrhosis, liver failure, and hepatocellular carcinoma. Ideally, clinical studies should demonstrate that hepatitis B therapies can prevent liver-related complications; however, these clinical endpoints evolve over years or decades. Therefore, clinical trials have relied on intermediate endpoints to evaluate the efficacy of treatment and to determine when treatment can be stopped. Intermediate endpoints that have been used include biochemical, histological, virological, and serological endpoints. This review will discuss the validity of these intermediate endpoints as surrogates of clinical endpoints, and the rates at which these intermediate endpoints can be achieved with currently available therapies.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/79271/1/j.1365-2893.2010.01369.x.pd

Prevention of recurrent hepatitis B post–liver transplantation

1 Factors associated with a lower rate of recurrent hepatitis B post–liver transplantation (LT) are negative hepatitis B e antigen and/or serum hepatitis B virus DNA pre-LT, hepatitis D virus superinfection, and fulminant hepatitis B. 2 Long-term intravenous hepatitis B immune globulin (HBIG) monotherapy can reduce the overall rate of recurrent hepatitis B to 20% to 35%. 3 Long-term lamivudine monotherapy is associated with a risk for drug resistance and overall 3-year rate of recurrent hepatitis B of 40% to 50%. 4 Combination prophylaxis with HBIG and lamivudine can reduce the overall rate of recurrent hepatitis B to 0% to 10%. 5 The dose and duration of HBIG therapy needed when used in combination with lamivudine may be lower, but the optimal regimen remains to be determined. 6 Lamivudine resistance before LT is associated with an increased risk for recurrent hepatitis B post-LT. 7 A cost-effective prophylactic regimen to prevent recurrent hepatitis B should be tailored according to risk.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/35278/1/500081013_ftp.pd

Reply:

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/87032/1/24410_ftp.pd

Chronic hepatitis B

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34785/1/510340622_ftp.pd

Reply

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34793/1/510370333_ftp.pd

Occult hepatitis B virus infection: A hidden menace?

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34784/1/510340128_ftp.pd

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72281/1/j.1365-2893.2002.00304.x.pd